Key result
A review of evidence from 4 decades of clinical trials suggests that the risk/benefit profile of beta-blockers and diuretics precludes their use as first-line therapy in hypertension.
Why the study?
Does first-line therapy with β-blockers and diuretics reduce clinical CVD events in patients with systemic arterial hypertension?
Does first-line therapy with β-blockers and diuretics reduce clinical CVD events in patients with systemic arterial hypertension?
Answers are grounded in this paper and cite their sources.
This review challenges historical practices by arguing that the risk/benefit profile of beta-blockers and diuretics does not support their use as first-line antihypertensive therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Messerli et al. (2008) conducted a review in Hypertension. β-Blockers and Diuretics was evaluated. A review of evidence from 4 decades of clinical trials suggests that the risk/benefit profile of beta-blockers and diuretics precludes their use as first-line therapy in hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: